Gsk Dividends - GSK

Gsk Dividends - GSK

Stock Name Stock Symbol Market Stock Type
Gsk Plc GSK London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
12.20 0.85% 1,439.60 16:35:16
Open Price Low Price High Price Close Price Previous Close
1,421.80 1,416.40 1,451.60 1,439.60 1,427.40
more quote information »
Industry Sector

Gsk GSK Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

Top Posts
Posted at 02/2/2023 10:01 by tradermichael
How is all this getting 'missed' by investors?

Even before GSK's corporate reshaping, which culminated with last summer's Haleon spinoff, the company has long held a leading presence in the HIV field via its ViiV Healthcare joint venture. Within the HIV franchise, GSK's new long-acting injectable therapy Cabenuva started to come into its own in 2022. The drug generated 340 million pounds last year, a sizable jump from 38 million pounds in 2021, when it won its initial FDA approval in January of that year.

Apretude, the company’s long-acting HIV prevention drug, has seen “very strong” demand after its approval in late 2021, Walmsley said Wednesday. Its sales totaled 41 million pounds in 2022. Like Cabenuva, GSK says it has negotiated favorable coverage for the drug in the U.S., so the company expects the launch to continue to gain steam in 2023.

Vaccines are another major financial driver for the company. GSK's star vaccine, Shingrix for shingles, suffered from a pandemic slowdown in 2020 and 2021, but the product is rolling once again. Riding a “post-pandemic rebound,” Shingrix delivered a record year in 2022, Chief Commercial Officer Luke Miels said a recent call. Sales reached 2.9 billion pounds last year, a whopping 60% increase from 2021.

GSK is also anticipating another big vaccine launch this year. The drugmaker submitted its respiratory syncytial virus vaccine candidate to regulators in the U.S., Europe and Japan. The shot is expected to become a blockbuster and vie for market share in this new arena against players such as Pfizer, Sanofi and Moderna.

Posted at 11/1/2023 10:15 by geckotheglorious
Some may be interested.

”GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference”

There is an option to listen to the pitch as well (Press Play Earnings Call button)

Posted at 05/12/2022 16:10 by geckotheglorious
last week.

GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.

The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.

In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.

Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.


Posted at 05/12/2022 14:55 by geckotheglorious
The ADRs of GSK plc (NYSE:GSK) dropped ~1% pre-market Monday after Bank of America downgraded its shares to Underperform from Neutral, arguing that the British drugmaker remains the firm’s least preferred name among the European majors.

Despite an “undemanding” PE multiple for 2024, “we see insufficient catalysts to rerate (GSK) shares near-term,” the analysts led by Graham Parry wrote, slashing their price target on the stock to 1450p from 1640p.

Noting the ~ £4B free cash flow the company generates, the analysts expect claims related to heartburn medication Zantac to weigh on GSK shares which, according to the analysts, more than discount their base case $4B liability risk.

Despite encouraging Phase 3 data, the analysts see no reason for GSK’s RSV vaccine to outcompete a rival shot from Pfizer (PFE). They also point out that the company has indicated a slower ramp for the RSV vaccine compared to its shingles vaccine Shingrix given the need to educate the public/physicians on the disease.

“While encouraged by GSK’s strong RSV vaccine PIII data we view Pfizer’s vaccine as credible competition given little to no perceived differentiation on efficacy and worse reactogenicity (tolerability) for GSK,” the team wrote.

They also argue that the company’s key franchises remain under pressure and a weak pipeline is unlikely to avoid an upcoming patent cliff in 2028/29E for HIV medication dolutegravir made worse by recent setbacks, including the recall of blood cancer therapy Blenrep.


Posted at 30/11/2022 20:22 by geckotheglorious
”GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.

The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.

In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.

Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.


Posted at 11/11/2022 14:42 by geckotheglorious
GSK drops as UBS cuts to Sell on 2027 “bottleneck”

GSK (NYSE:GSK) lost ~4% pre-market Friday after UBS downgraded the British drugmaker to Sell from Hold, questioning the durability of the company’s HIV franchise and revenue from its shingles vaccine Shingrix beyond 2027.

The analysts led by Michael Leuchten estimate a ~20% revenue hit to the company when Shingrix reaches the peak penetration in the U.S. catch-up population in 2027 and HIV therapy dolutegravir faces a patent cliff around the same timeframe.

The analysts think the current consensus for GSK (GSK) fails to recognize the uncertainty over the HIV franchise and implies more than £2B Shingrix revenue than feasible.

The company has time to adjust R&D options and earmark additional capital (£20B – £30B) to tide over the 2027 “bottleneck,” but “this could mean earnings dilution,” the team added, lowering the 12-month price target on GSK (GSK) to 1,300p from 1,820p.


Posted at 03/11/2022 09:06 by stewart64
I wasn't a holder of GSK on demerger day, so didn't go into the mechanics at that time. But wondered if someone can answer this query please. I understand that 5 shares in old GSK became 4 shares in new GSK. Yet Haleon is worth considerably more than one quarter of new GSK. Therefore why didn't the price of new GSK go down on demerger day? Or did the price adjustment occur later and by what factor.

As I'm assuming comparing the old and new GSK price isn't comparing like with like?

Posted at 02/11/2022 10:24 by tradermichael
The Zantac litigation continues in federal and state courts in the
United States. GSK's position on the scientific validity of these
cases has not changed since the last reporting period. GSK will continue
to defend all claims vigorously.

GSK has been named as a co-defendant in approximately 4,100 filed
personal injury cases in federal and state court. There are approximately
77,000 plaintiffs named in these cases. A significant majority of
these plaintiffs were named in a series of multi-plaintiff complaints
recently filed in Delaware state court and most of these plaintiffs
were previously in the Multidistrict Litigation (MDL) Census Registry
in the Southern District of Florida. They were removed because they
allege a cancer other than the 5 cancers being pursued by the MDL
plaintiffs. In the MDL, plaintiffs originally identified 10 different
types of cancers they wished to pursue. Plaintiffs subsequently dropped
5 of the 10 cancers, and they are proceeding only as to bladder,
esophageal, gastric, liver, and pancreatic, although plaintiffs in
state courts continue to pursue claims beyond the 5 designated cancers.
There are approximately 33,000 unfiled claims relating to GSK and
other co-defendants concerning the 5 designated cancers in the MDL
Census Registry. There are also over 2,000 California state court
cases subject to an agreement between GSK and the plaintiffs which
suspends the statute of limitations to allow the plaintiffs to bring
their claims at a later date. These filed and unfiled counts are
subject to change.

As planned, in September and October 2022, the MDL Court held hearings
on the admissibility of each side's general causation expert witnesses
("Daubert hearings"). Based on the 12 epidemiological studies conducted
looking at human data regarding the use of ranitidine, the scientific
consensus is that there is no consistent or reliable evidence that
ranitidine increases the risk of any type of cancer. The 12th additional
epidemiologic study (Wang et al. (2022)) was recently released. When
comparing ranitidine to an active comparator (famotidine), Wang 2022
found a statistically significant increased risk with regard to liver
cancer (Hazard Ratio 1.22, 95% Confidence Interval 1.06-1.40) and
no statistically significant increased risk for the remaining 4 cancers
pursued in the MDL. Consistency across available epidemiological
evidence, particularly where reported potential associations are
modest, is critical for drawing reliable conclusions about causation.
The parties await a decision from Judge Robin L. Rosenberg.

In the California Zantac litigation Cases JCCP 5150 (JCCP), the Court
will hold a Sargon hearing on 25 January 2023 regarding the admissibility
of expert witnesses, including general causation expert witnesses,
for the first bellwether trials. The first bellwether trial is expected
to start on 13 February 2023 in the California JCCP.

The Illinois Supreme Court recently consolidated all Illinois ranitidine
cases in Cook County for pretrial proceedings with trial dates to
be set, including the previously scheduled Madison County trial.

Given the complex ownership and marketing of Zantac prescription
and over-the-counter (OTC) medicine over many years, numerous claims
involve several defendants. As a result, some defendants have served
one another, including GSK, with notice of potential indemnification
claims about possible liabilities connected particularly with Zantac
OTC. Given the early stage of the proceedings, GSK cannot meaningfully
assess what liability, if any, it may have, nor can it meaningfully
assess the liability of other parties under relevant indemnification

Further information regarding the litigation can be found in GSK's
11 August 2022 and 16 August 2022 statements.

Posted at 02/11/2022 08:44 by tradermichael
Don't forget OLD GSK = New GSK + HLN. Then understand that for Haleon, analysts estimate an annual dividend of six pence a share in 2023 and seven pence in 2024. So longer term holders can add that to their GSK dividend income .... ;0)
Posted at 13/10/2022 07:01 by tradermichael
Yes spyder, truly exceptional results:

GSK's older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

-- Data to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favourable safety profile

-- Consistent high vaccine efficacy observed against LRTD in severe disease (94.1%), adults aged 70-79 years (93.8%) and in adults with underlying comorbidities (94.6%)

-- High vaccine efficacy is consistent across RSV A and B strains
GSK plc (LSE/NYSE: GSK) today announced positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above to be presented at IDWeek 2022. The vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% CI, 57.9-94.1, 7 of 12,466 vs. 40 of 12,494) against RSV lower respiratory tract disease (RSV-LRTD), meeting the trial's primary endpoint.

Consistent high vaccine efficacy was also observed across a range of pre-specified secondary endpoints, highlighting the impact the vaccine candidate could have on the populations most at risk of the severe outcomes of RSV. Efficacy against severe RSV-LRTD, defined as LRTD with at least two lower respiratory signs or assessed as severe by the investigator and confirmed by the external adjudication committee, was 94.1% (95% CI, 62.4-99.9, 1 of 12,466 vs. 17 of 12,494). In participants with pre-existing comorbidities, such as underlying cardiorespiratory and endocrinometabolic conditions, vaccine efficacy was 94.6% (95% CI, 65.9-99.9, 1 of 4,937 vs. 18 of 4,861), with 93.8% (95% CI, 60.2-99.9, 1 of 4,487 vs. 16 of 4,487) efficacy observed in adults aged 70-79 years.

Vaccine efficacy against LRTD was consistent across both RSV-A and RSV-B subtypes (84.6%; CI 32.1-98.3, 2 of 12,466 vs. 13 of 12,494 and 80.9%; CI 49.4-94.3, 5 of 12,466 vs. 26 of 12,494 respectively), consistent with the robust neutralising antibody response generated against both subtypes. See Figure 1: Vaccine efficacy against first episodes of RSV-confirmed LRTD and RSV-confirmed ARI (modified exposed set).

Tony Wood, GSK Chief Scientific Officer, said: "These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research. We believe that with the high vaccine efficacy demonstrated in this pivotal trial, our vaccine candidate has the potential to help reduce the significant global burden of RSV-associated disease in older adults, including those at the greatest risk of severe outcomes due to their age or underlying comorbidities."

The vaccine was well tolerated with a favourable safety profile. The observed solicited adverse events were typically mild-to-moderate and transient, the most frequent being injection site pain, fatigue, myalgia, and headache.

Regulatory submissions based on the phase III data are anticipated in the second half of 2022. GSK's RSV vaccine candidate for older adults contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's proprietary AS01(E) adjuvant. There are currently no RSV vaccines approved anywhere in the world.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230205 10:23:59